Problem
1)	What were the benefits and costs of developing a human version of ivermectin?
2)	Why did Dr. P. Roy Vagelos and his team ultimately decide to develop a human version of ivermectin?
3)	How do you think Merck's investments in the human version of ivermectin create value for its stakeholders and corporate goodwill?